Cantargia presents clinical data from its ongoing CANFOUR trial at ESMO
Cantargia AB (publ) today announced that interim results from its clinical Phase I/II trial of lead candidate CAN04 (nidanilimab) will be presented in a poster presentation at the ESMO Congress 2018 in Munich, Germany, on October 20, 2018.The poster presentation – with the title A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumors – will be given by the coordinating investigator Professor Ahmad Awada, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. The poster is